Hemogen Gene Biotechnology

Hemogen Gene Biotechnology is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the development of transformative gene and cell therapies for hematological and genetic disorders. The company's core expertise lies in its proprietary lentiviral vector platform, which it utilizes to engineer autologous hematopoietic stem cells for the treatment of severe blood diseases. Its lead candidate, HMG001, is currently undergoing Phase 1/2 clinical evaluation for transfusion-dependent beta-thalassemia, showing promising potential as a one-time curative treatment. Beyond its lead program, Hemogen is advancing a pipeline of therapies for sickle cell disease and other rare conditions. As an affiliate of the prominent CDMO OBiO Technology, Hemogen benefits from robust internal manufacturing and process development capabilities. The company aims to address significant unmet medical needs in the field of rare genetic diseases through innovative genetic engineering.